Sign in
Active, not recruitingPhase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

Key facts

Who runs it
Hoffmann-La Roche
Where
Aurora, Birmingham, Boston, Cleveland, Milwaukee, New York, Newport Beach, Rochester, San Francisco, and Washington D.C., United StatesSee the 11 sitesAlso in 16 other countries, 56 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
122 people enrolled
Started
27 Sept 2022
Expected to end
14 Dec 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Satralizumab
  • Placebo
Record updated
8 October 2026

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 42 criteriaShow less

Who can take part

  • Reasonable exclusion of tumor or malignancy before baseline visit (randomization)
  • Onset of AIE symptoms ≤ 9 months before randomization
  • Meet the definition of "New Onset" or "Incomplete Responder" AIE
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for at least 3 months after the final dose of satralizumab or placebo
  • For participants enrolled in the extended China enrollment phase at China's sites: participants who are current residents of mainland China, Hong Kong, or Taiwan, and of Chinese ancestry; NMDAR AIE Cohort:
  • Age ≥ 12 years
  • Diagnosis of probable or definite NMDAR encephalitis; LGI1 AIE Cohort
  • Age ≥ 18 years
  • Diagnosis of LGI1 encephalitis

Who cannot take part

  • History of carcinoma or malignancy, unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening
  • Historically known positivity to any cell surface neuronal antibodies other than NMDAR and LGI1, in the absence of NMDAR and LGI1 antibody positivity
  • History of herpes simplex virus encephalitis in the previous 24 weeks
  • Any previous/concurrent treatment with interleukin-6 (IL-6) inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation, or bone marrow transplantation
  • Any previous treatment with T-cell depleting therapies, cladribine, or mitoxantrone
  • Treatment with oral cyclophosphamide within 1 year prior to baseline
  • Treatment with any investigational drug (including bortezomib) within 24 weeks prior to screening
  • Concurrent use of more than one immunosuppressive therapy (IST) as background therapy
  • Contraindication to all of the following rescue treatments: rituximab, intravenous immunoglobulin (IVIG), high-dose corticosteroids, or intravenous (IV) cyclophosphamide
  • Any surgical procedure, except laparoscopic surgery or minor surgeries within 4 weeks prior to baseline, excluding surgery for thymoma or teratoma removal
  • Planned surgical procedure during the study
  • Evidence of serious uncontrolled concomitant diseases
  • Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit
  • History of drug or alcohol abuse within 1 year prior to baseline
  • History of diverticulitis or concurrent severe gastrointestinal (GI) disorders that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation
  • Receipt of live or live-attenuated vaccine within 6 weeks prior to baseline visit
  • History of suicide attempt within 3 years prior to screening except if this is clearly associated with and occurs during the acute phase of LGI-1 or NMDAR encephalitis
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of study drug
  • For participants with NMDAR AIE, history of negative anti-NMDAR antibody in cerebrospinal fluid (CSF) using a cell-based assay within 9 months of symptom onset
  • Historically known positivity to an intracellular antigen with high cancer association or glutamate decarboxylase 65 (GAD-65)
  • Confirmed central nervous system (CNS) or peripheral nervous system (PNS) demyelinating disease
  • Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection
  • Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection
  • Positive hepatitis B (HBV) and hepatitis C (HCV) test at screening
  • Evidence of latent or active tuberculosis (TB)
  • History of severe allergic reaction to a biologic agent
  • Any previous treatment with anti-cluster of differentiation 19 antibody (CD19 antibody), complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody
  • History of blood donation (1 unit or more), plasma donation or platelet donation within 90 days prior to screening
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes safe participation in and completion of the study
  • Any untreated teratoma or thymoma at baseline visit (randomization)
  • Confirmed paraneoplastic encephalitis
  • Alternative causes of associated symptoms
  • Evidence of progressive multifocal leukoencephalopathy

Where in United States

Also in 16 other countries, 56 sites

  • University of ColoradoAurora, United States
  • University of Alabama at BirminghamBirmingham, United States
  • Brigham and Women's Hospital Department of NeurologyBoston, United States
  • Cleveland Clinic FoundationCleveland, United States
  • University Hospitals Of ClevelandCleveland, United States
  • Medical College of WisconsinMilwaukee, United States
  • NYU Langone Medical CenterNew York, United States
  • Hoag Memorial HospitalNewport Beach, United States
  • Mayo Clinic - RochesterRochester, United States
  • UCSF- Multiple Sclerosis CentreSan Francisco, United States
  • Childrens National Health CenterWashington D.C., United States

About the trial

What the trial wants to find out

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

The 4 groups in the trial

  • NMDAR Autoimmune Encephalitis (AIE) CohortTreatment being tested

    Adults and adolescents with definite or probable NMDAR encephalitis will receive satralizumab as per the schedule specified in the protocol. As of Protocol Version 6, participants in Part 1 will transition to Part 2 at the time of primary analysis or at Week 52, whichever occurs first.

    Treatment: Satralizumab

  • LGI1 AIE CohortTreatment being tested

    Adults with LGI1 encephalitis as per the schedule specified in the protocol.

    Treatment: Satralizumab

  • NMDAR AIE Placebo CohortPlacebo, for comparison

    Adults and adolescents with definite or probable NMDAR encephalitis will receive satralizumab placebo as per the schedule specified in the protocol. As of Protocol Version 6, participants in Part 1 will transition to Part 2 at the time of primary analysis or at Week 52, whichever occurs first.

    Treatment: Placebo

  • LGI1 AIE Placebo CohortPlacebo, for comparison

    Adults with LGI1 encephalitis will receive satralizumab placebo as per the schedule specified in the protocol.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Record updated
8 October 2026